Urology Times September 12, 2024
“In the period where a patient receives a diagnosis of favorable intermediate-risk cancer or higher and doesn’t know what to do, there is a big unmet need/gap that we aim to serve with Unfold AI,” says Shyam Natarajan, PhD.
In this video, Shyam Natarajan, PhD, shares how Unfold AI compares with other AI-based tools that are currently available for prostate cancer detection and staging. He is an author of the recent BJUI Compass study, “Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm.” Natarajan is the founder and CEO of Avenda Health.
Transcription:
How does Unfold AI compare to other AI-based tools that are currently available for prostate cancer detection and staging?
Other AI-based algorithms and systems...
Today's Sponsors
Today's Sponsor